TNGX
Tango Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -30.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +22 | 90.51M | $2.83B | +24 | −2 |
| Q1 2026 | 77 | 0 | 72.21M | $1.51B | +9 | −9 |
| Q4 2025 | 76 | 0 | 64.83M | $574.42M | +1 | −1 |
| Q3 2025 | 19 | +2 | 27.21M | $228.58M | +3 | −1 |
| Q2 2025 | 14 | 0 | 22.55M | $115.47M | +1 | −1 |
| Q1 2025 | 11 | +1 | 6.63M | $9.09M | +2 | −1 |
| Q4 2024 | 10 | 0 | 4.99M | $15.42M | +3 | −3 |
| Q3 2024 | 9 | -1 | 6.83M | $52.57M | +1 | −2 |
| Q2 2024 | 10 | — | 5.64M | $48.44M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 1.63M | -39.6% | $5.03M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.39M | +1.3% | $4.29M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 1.23M | — | $3.80M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 249.65K | New | $771,406 | 0.0% | New | 1 | SEC ↗ |
| 5 | Fisher Asset Management ✦ | 154.95K | 0.0% | $478,786 | 0.0% | Held | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 138.25K | -3.5% | $427,183 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 114.83K | New | $354,815 | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 45.00K | -34.0% | $139,038 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 21.50K | New | $66,435 | 0.0% | New | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 21.00K | +29.7% | $65,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $771,406 | 0.0% |
| D. E. Shaw & Co. | $354,815 | 0.0% |
| Renaissance Technologies | $66,435 | 0.0% |
Exited
| Adage Capital Partners | $17.67M | was 0.0% |
| Marshall Wace | $563,040 | was 0.0% |
| AQR Capital Management | $109,386 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 180.17M shares, $3.72B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 600 sh · $15,192
Officer · 26.40K sh · $645,604
Officer · 2.40K sh · $60,412
Officer · 700 sh · $15,962
Officer · 5.10K sh · $122,238
Officer · 27.00K sh · $603,909
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology